<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="212470">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320424</url>
  </required_header>
  <id_info>
    <org_study_id>AR3106335</org_study_id>
    <nct_id>NCT00320424</nct_id>
  </id_info>
  <brief_title>Hip Fracture Study of GSK576428 (Fondaparinux Sodium)</brief_title>
  <official_title>Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Hip Fracture Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study is requested by PMDA to confirm the efficacy and the safety for HFS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of adjudicated VTE (venous thromboembolism) [DVT (deep vein thrombosis) or PE] based on the assessment of venograms.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of PE, DVT, proximal DVT, distal only DVT</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Hip Fracture</condition>
  <condition>Surgery</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fondaparinux</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing hip fracture surgery within 10 days following the time of
             fracture of the hip (proximal femur) (or following the time of fracture estimated
             from trauma).

        Exclusion Criteria:

          -  Active, clinically significant bleeding (excluding drainage).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>October 2010</verification_date>
  <lastchanged_date>October 1, 2010</lastchanged_date>
  <firstreceived_date>May 1, 2006</firstreceived_date>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>MOSLL</keyword>
  <keyword>VTE</keyword>
  <keyword>Xa factor</keyword>
  <keyword>pentasaccharide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
